Incyte announces that TRuE-AD2 trial of ruxolitinib cream met its primary endpoint in patients with atopic dermatitis
Incyte announced positive topline results from its randomized, vehicle-controlled, pivotal Phase 3 TRuE-AD2 study evaluating the safety and efficacy of ruxolitinib cream in adolescent and adult patients (age ≥ 12 years) with atopic dermatitis (AD).